Compare Blackrock Inc (BLK) vs Eli Lilly And Co (LLY) Price & Performance

BlackRock (BLK) trades at $1,031.56, down 0.44% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results anticipated. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. The company maintains robust profitability metrics, including a 24.4% net income margin and 11.95% ROE. Recent news highlights the launch of a new Nasdaq-100 ETF, IQQ, challenging Invesco's QQQ.

The outlook for BLK remains positive, driven by earnings momentum, strategic ETF expansion, and solid institutional support. Key risks include market volatility affecting asset management fees and competitive pressures in the ETF space. With 76% of analysts rating it a Buy and a consensus price target of $1,290, the stock presents a compelling opportunity for growth-oriented investors, though monitoring Q2 earnings and macroeconomic trends is essential.

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.